The mission of this Shared Resource is to provide histologic and hematopoietic research support services to UCSF Comprehensive Cancer Center (CCC) investigators studying the pathogenesis and treatment of organ and hematologic malignancies in mouse models of human cancer. This facility provides services for members of many of the CCC programs. Histology services include processing, embedding, and histologic sectioning of murine tissues in paraffin and frozen blocks (with re-embedding of tissue as necessary), routine histochemical staining (hematoxylin and eosin) and other special histochemical stains. The Shared Resource also provides expertise in murine hematology. Complete blood counts are provided for investigators, including preparation of blood smears for analysis of white blood cell, red blood cell, and platelet morphology. In addition, the Shared Resource assists investigators analyzing hematopoietic tissues, including cytologic and histologic preparations of bone marrow, spleen, and lymph nodes. Another service provided by the Shared Resource is access to outside veterinary laboratory testing (e.g. serum chemistry assays). The Shared Resource runs a mouse pathology workshop, provides pathologic consultation, and provides both training on and access to the equipment utilized for pathologic analyses of mice. The Mouse Pathology Shared Resource was used by laboratory personnel representing 50 different investigators at the CCC, providing a total of 14,051 units of service during the most recent 12 month period. Investigators in many of the CC programs have relied upon the Shared Resource not only for direct services, but also for the training of their personnel. The results of the Mouse Pathology Shared Resource are evident in the extensive publications that reflect the use of mouse models by the investigators that utilize this service.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-10
Application #
7619939
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
10
Fiscal Year
2008
Total Cost
$65,009
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28

Showing the most recent 10 out of 192 publications